Abstract
Extensive nerve cell death occurs during the development of the central nervous system as well as in episodes of trauma and in neurodegenerative disease. The mechanistic details of how these cells die are poorly understood. Here we describe a unique oxidative stress-induced programmed cell death pathway called oxytosis, and outline pharmacological approaches which interfere with its execution. Oxidative glutamate toxicity, in which exogenous glutamate inhibits cystine uptake through the cystine/glutamate antiporter leading to a depletion of glutathione, is used as an example of oxytosis. It is shown that there is a sequential requirement for de novo macromolecular synthesis, lipoxygenase activation, reactive oxygen species production, and the opening of cGMP-gated channels which allow the influx of extracellular calcium. The translation initiation factor eIF2α plays a central role in this pathway by regulating the levels of glutathione. Finally, examples are given in which the reduction in glutathione, the production of reactive oxygen species, and calcium influx can be experimentally manipulated to prevent cell death. Data are reviewed which suggest that oxytosis may be involved in nerve cell death associated with nervous system trauma and disease.
Current Topics in Medicinal Chemistry
Title: Oxytosis: A Novel Form of Programmed Cell Death
Volume: 1 Issue: 6
Author(s): Shirlee Tan, David Schubert and Pamela Maher
Affiliation:
Abstract: Extensive nerve cell death occurs during the development of the central nervous system as well as in episodes of trauma and in neurodegenerative disease. The mechanistic details of how these cells die are poorly understood. Here we describe a unique oxidative stress-induced programmed cell death pathway called oxytosis, and outline pharmacological approaches which interfere with its execution. Oxidative glutamate toxicity, in which exogenous glutamate inhibits cystine uptake through the cystine/glutamate antiporter leading to a depletion of glutathione, is used as an example of oxytosis. It is shown that there is a sequential requirement for de novo macromolecular synthesis, lipoxygenase activation, reactive oxygen species production, and the opening of cGMP-gated channels which allow the influx of extracellular calcium. The translation initiation factor eIF2α plays a central role in this pathway by regulating the levels of glutathione. Finally, examples are given in which the reduction in glutathione, the production of reactive oxygen species, and calcium influx can be experimentally manipulated to prevent cell death. Data are reviewed which suggest that oxytosis may be involved in nerve cell death associated with nervous system trauma and disease.
Export Options
About this article
Cite this article as:
Shirlee Tan , David Schubert and Pamela Maher , Oxytosis: A Novel Form of Programmed Cell Death, Current Topics in Medicinal Chemistry 2001; 1 (6) . https://dx.doi.org/10.2174/1568026013394741
DOI https://dx.doi.org/10.2174/1568026013394741 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tau Silencing by siRNA in the P301S Mouse Model of Tauopathy
Current Gene Therapy In silico Methods for Designing Antagonists to Anti-apoptotic Members of Bcl-2 Family Proteins
Mini-Reviews in Medicinal Chemistry Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Hutchinson-Gilford Progeria Syndrome: An Overview of the Molecular Mechanism, Pathophysiology and Therapeutic Approach
Current Gene Therapy Amyotrophic Lateral Sclerosis and Excitotoxicity: From Pathological Mechanism to Therapeutic Target
CNS & Neurological Disorders - Drug Targets Autophagy after Subarachnoid Hemorrhage: Can Cell Death be Good?
Current Neuropharmacology Cross-Talk Between NO Synthase Isoforms in Neuro-Inflammation: Possible Implications in HIV-Associated Neurocognitive Disorders
Current Medicinal Chemistry Novel Pharmacological Targets for Controlling Dendrite Branching and Growth During Neuronal Development
Central Nervous System Agents in Medicinal Chemistry Clinical Neurophysiology of Brain Plasticity in Aging Brain
Current Pharmaceutical Design Targeting Stress Activated Protein Kinases, JNK and p38, as New Therapeutic Approach for Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Nasal Neuro EPO Could be a Reliable Choice for Neuroprotective Stroke Treatment
Central Nervous System Agents in Medicinal Chemistry Modulating Mitophagy in Mitochondrial Disease
Current Medicinal Chemistry Serum Starvation Induces BACE1 Processing and Secretion
Current Alzheimer Research Gels and Jellies as a Dosage Form for Dysphagia Patients: A Review
Current Drug Therapy Update of QSAR & Docking Studies of the GSK-3 Inhibitors
Current Bioinformatics Recent Patent Advances for Neurodegenerative Disorders and its Treatment
Recent Patents on Drug Delivery & Formulation Capillary Electrophoresis Interfaced with a Mass Spectrometer (CE-MS): Technical Considerations and Applicability for Biomarker Studies in Animals
Current Protein & Peptide Science Deep Eutectic Solvents: An Alternative Medium for the Preparation of Organosulfur Compounds
Current Green Chemistry Arachidonic Acid Metabolites in Neurologic Disorders
CNS & Neurological Disorders - Drug Targets A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research